Abstracts Archive - Page 1303 of 2425 - ACR Meeting Abstracts

Abstract Number: 1462 • 2017 ACR/ARHP Annual Meeting
Induction of Immune Tolerance through an Epitope-Specific Vaccine Induces Clinical Amelioration in Patients with Rheumatoid Arthritis
Jin Hui Sherlynn Chan¹, Theodorus van den Broek², Jing Yao Leong¹, Maura Rossetti³, Roberto Spreafico⁴ and Salvatore Albani^1,5, ¹SingHealth Translational Immunology and Inflammation Centre (STIIC), Duke-NUS Medical School, Singapore, Singapore, ²University Medical Center of Utrecht, Utrecht, Netherlands, ³University of California, Los Angeles, Los Angeles, CA, ⁴Synthetic Genomics, La Jolla, CA, ⁵KK Women's and Children's Hospital, Singapore, Singapore
Background/Purpose: The manipulation of immune tolerance using immune checkpoints such as PD-1 is gaining progressive attraction in diseases such cancer where such manipulation would be…
Abstract Number: 1463 • 2017 ACR/ARHP Annual Meeting
Interaction between Methotrexate and BAFF for Preventing Immunization Against TNF-α Inhibitors By Increasing Adenosine and Regulatory B-Cell Subsets
Samuel Bitoun¹, Gaetane Nocturne², Bineta Ly³, Juliette Pascaud⁴, Alain Pruvost⁵ and X Mariette⁶, ¹INSERM U1184, IMVA, Paris Sud University,LabEx LERMIT, Le Kremlin Bicëtre, France, ²INSERM U1184, IMVA, Paris Sud University,LabEx LERMIT, Le Kremlin Bicêtre, France, ³INSERM U1184, Paris Sud University, Kremlin Bicetre, France, ⁴U1184 IMVA, Université Paris Sud, Le Kremlin-Bicêtre Cedex, France, ⁵CEA - DRF/iBiTec-S - LabEx LERMIT - MetaboHUB-Paris, Gif sur Yvette, France, ⁶INSERM U1184, Université Paris-Sud, Hôpitaux Universitaires Paris-Sud, Le Kremlin-Bicêtre, France
Background/Purpose: TNFα inhibitors (TNFi) can be immunogenic in patients with autoimmune diseases. B-cell activating factor transgenic mice (BAFFtg) are a model of autoimmune disease since…
Abstract Number: 1464 • 2017 ACR/ARHP Annual Meeting
Relation of HLA-DRB1 Genotype to the Efficacies of Abatacept and Tocilizumab in Patients with Rheumatoid Arthritis
Kensuke Oryoji, The Center for Rheumatology, Matsuyama Red Cross Hospital, Ehime, Japan
Background/Purpose: To investigate whether clinical efficacy of abatacept (ABT) and tocilizumab (TCZ) differs depending on whether or not HLA-DRB1 Shared Epitope (SE) is present in…
Abstract Number: 1465 • 2017 ACR/ARHP Annual Meeting
Cost per Response for Abatacept Versus Adalimumab in Patients with Seropositive, Erosive, Early Rheumatoid Arthritis in the US, Germany, Spain and Canada
J Foo¹, JM Rodriguez Heredia², C Polanco Sánchez³, M Mtibaa⁴, KH Herrmann⁵, E Alemao⁶, R Postema⁷ and C Baerwald⁸, ¹Mapi Group, Houten, Netherlands, ²Hospital Universitario de Getafe, Madrid, Spain, ³Bristol-Myers Squibb, Madrid, Spain, ⁴Bristol-Myers Squibb, Montréal, QC, Canada, ⁵Bristol-Myers Squibb, Munich, Germany, ⁶Bristol-Myers Squibb, Princeton, NJ, ⁷Bristol-Myers Squibb, Uxbridge, United Kingdom, ⁸University Hospital, Department of Internal Medicine, Rheumatology Unit, Leipzig, Germany
Background/Purpose: RA is a chronic, inflammatory disorder leading to disability and reduced quality of life. Effective treatment with biologic DMARDs poses a significant economic burden.…
Abstract Number: 1466 • 2017 ACR/ARHP Annual Meeting
The Effects of Rituximab and B-Cells Depletion on the Inflammatory and Pro-Thrombotic Profile of Leucocytes of Rheumatoid Arthritis Patients and on the Vascular Endothelium
Irene Cecchi¹, Carlos Perez-Sanchez², Patricia Ruiz-Limon³, Ivan Arias de la Rosa³, Maria Carmen Abalos-Aguilera³, Yolanda Jiménez-Gómez², Rafaela Ortega-Castro², Eduardo Collantes-Estévez², Alejandro Escudero-Contreras³, Massimo Radin⁴, Nuria Barbarroja², Dario Roccatello⁵, Savino Sciascia⁶ and Chary Lopez-Pedrera⁷, ¹Center of Research of Immunopathology and Rare Diseases- Coordinating Center of Piemonte and Valle d’Aosta Network for Rare Diseases, Department of Clinical and Biological Sciences, University of Turin, Italy, Turin, Italy, ²Rheumatology service, IMIBIC/Reina Sofia Hospital/University of Cordoba, Cordoba, Spain, ³Rheumatology Service, IMIBIC/Reina Sofia Hospital/University of Cordoba, Cordoba, Spain, ⁴Department of Clinical and Biological Sciences, Center of Research of Immunopathology and Rare Diseases- Coordinating Center of Piemonte and Valle d’Aosta Network for Rare Diseases, Department of Clinical and Biological Sciences, University of Turin, Italy, Turin, Italy, ⁵Center of Research of Immunopathology and Rare Diseases- Coordinating Center of Piemonte and Valle d’Aosta Network for Rare Diseases, Department of Clinical and Biological Sciences, University of Turin, Italy, Center of Research of Immunopathology and Rare Diseases- Coordinating Center of Piemonte and Valle d’Aosta Network for Rare Diseases, Department of Clinical and Biological Sciences, University of Turin, Italy, Turin, Italy, ⁶Center of Research of Immunopathology and Rare Diseases- Coordinating Center of Piemonte and Valle d’Aosta Network for Rare Diseases, Department of Clinical and Biological Sciences, University of Turin, Italy, Center of Research of Immunopathology and Rare Diseases- Coordinating Center of Piemonte and Valle d’Aosta Network for Rare Diseases, Department of Clinical and Biological Sciences, University of Turin, Italy, Torino, Italy, ⁷IMIBIC/Reina Sofia Hospital/ University of Cordoba, Cordoba, Spain
Background/Purpose: Cardiovascular disease (CVD) constitutes a relevant cause of morbidity and mortality in Rheumatoid Arthritis (RA) patients. Rituximab (RTX) has been proved to be effective…
Abstract Number: 1467 • 2017 ACR/ARHP Annual Meeting
Changes in the Immune Response of RA Patients Induced By 1 Year of Tocilizumab
Cesar Diaz-Torné¹, Paula Estrada², Patricia Moya³, Maria A. Ortiz⁴, Diana de la Fuente⁵, Mireia Moreno⁶, Noemí Busquets⁷, Julio Ramírez⁸, Carme Moragues⁹, Sergi Ros⁵, Enrique Casado Burgos⁶, Vicente Torrente¹⁰, Elizabeth Garcia¹¹, Manel Pujol¹², Andrés Ponce¹³, Silvia Vidal⁴ and Juan José de Agustín¹⁴, ¹Rheumatology, Hospital Universitari de la Santa Creu i Sant Pau, Barcelona, Spain, ²Rheumatology, Hospital Moisès Broggi-Hospital General de L´Hospitalet. Consorci Sanitari Integral, Barcelona, Spain, ³Hospital de la Santa Creu i Sant Pau, Barcelona, Spain, ⁴Institut de Recerca Sant Pau, Barcelona, Spain, ⁵Rheumatology, Hospital de Viladecans, Viladecans, Spain, ⁶Rheumatology, Parc Tauli Hospital Universitari, Sabadell, Spain, ⁷Rheumatology, Hospital General de Granollers, Granollers, Spain, ⁸Rheumatology Service, Hospital Clínic de Barcelona, Barcelona, Spain, ⁹Rheumatology, Hospital de la Santa Creu i Sant Pau, Barcelona, Spain, ¹⁰Hospital Moisès Broggi-Hospital General de L´Hospitalet. Consorci Sanitari Integral, L'Hospitalet de Llobregat, Spain, ¹¹Rheumatology, Hospital de Mollet, Mollet, Spain, ¹²Hospital Mútua de Terrassa, Terrassa, Spain, ¹³Rheumatology. Internal Medicine, Hospital General de Granollers, Granollers, Spain, ¹⁴Rheumatology, Hospital Vall d´Hebrón, Barcelona, Spain
Background/Purpose: Tocilizumab, a humanized anti-human IL-6 receptor antibody that blocks the signaling of IL-6/IL-6R complex, is an effective treatment in chronic inflammatory rheumatoid arthritis (RA).…
Abstract Number: 1468 • 2017 ACR/ARHP Annual Meeting
Abatacept Retention Rates, Overall and By Participating Country, and Prognostic Factors of Retention in Patients with RA: 2-Year Results from a Real-World Observational Study
Rieke Alten¹, HM Lorenz², X Mariette³, HG Nüßlein⁴, M Galeazzi⁵, F Navarro⁶, M Chartier⁷, Y Elbez⁸, C Rauch⁹ and M Le Bars⁷, ¹Schlosspark-Klinik University Medicine, Berlin, Germany, ²University Hospital, Heidelberg, Germany, ³Université Paris-Sud, Paris, France, ⁴University of Erlangen, Nürnberg, Germany, ⁵University of Siena, Siena, Italy, ⁶Hospital Universitario Virgen Macarena, Seville, Spain, ⁷Bristol-Myers Squibb, Rueil-Malmaison, France, ⁸Excelya, Boulogne-Billancourt, France, ⁹Bristol-Myers Squibb, Munich, Germany
Background/Purpose: ACTION (NCT02109666) was the first prospective international non-interventional study designed to provide long-term real-world data on abatacept retention in patients (pts) with RA. The…
Abstract Number: 1469 • 2017 ACR/ARHP Annual Meeting
Treatment Paradigms in Real-World Practice: Biologic Agent Use Prior to and after Discontinuation of Abatacept
Rieke Alten¹, H-M Lorenz², X Mariette³, H Nüßlein⁴, M Galeazzi⁵, F Navarro⁶, M Chartier⁷, Y Elbez⁸, C Rauch⁹ and M Le Bars⁷, ¹Schlosspark-Klinik University Medicine, Berlin, Germany, ²University Hospital, Heidelberg, Germany, ³Université Paris-Sud, Paris, France, ⁴University of Erlangen-Nuremberg, Nuremberg, Germany, ⁵University of Siena, Siena, Italy, ⁶Hospital Universitario Virgen Macarena, Seville, Spain, ⁷Bristol-Myers Squibb, Rueil-Malmaison, France, ⁸Excelya, Boulogne-Billancourt, France, ⁹Bristol-Myers Squibb, Munich, Germany
Background/Purpose: ACTION is a 2-year, observational study of patients (pts) with moderate-to-severe RA who initiated IV abatacept in Canada and Europe (NCT02109666). The objective was…
Abstract Number: 1470 • 2017 ACR/ARHP Annual Meeting
Impact of Anti-Drug Antibody and Injection Site Reaction on Efficacy: 24-Week Results from a Phase III Study Comparing SB4 (etanercept biosimilar) with Reference Etanercept in Patients with Rheumatoid Arthritis
Jiri Vencovsky¹, Paul Emery², Edward C. Keystone³, Jeehoon Ghil⁴, Soo Yeon Cheong⁴ and Evelyn Hong⁴, ¹Institute of Rheumatology, Deartment of Rheumatology, 1st Faculty of Medicine, Charles University, Prague, Czech Republic, ²NIHR-Leeds Musculoskeletal Biomedical Research Unit and Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, Leeds, United Kingdom, ³University of Toronto, Toronto, ON, Canada, ⁴Samsung Bioepis Co., Ltd., Incheon, Korea, Republic of (South)
Background/Purpose : SB4 is approved by the European Commission as a biosimilar of the reference etanercept (ETN). The phase III clinical study results have been…
Abstract Number: 1471 • 2017 ACR/ARHP Annual Meeting
Flare Incidence and Predictive Factors in a Population of Patients with Rheumatoid Arthritis Under Optimised Treatment with Adalimumab and Infliximab
Amara Pieren¹, Dora Pascual-Salcedo², Pilar Aguado³, Gema Bonilla⁴, Eugenio De Miguel⁵, Irene Monjo⁶, Laura Nuño³, Diana Peiteado³, Alejandro Villalba³, Enrique Moral Coro⁴, C. Tornero⁷, Patricia Bogas⁴, Alejandro Balsa³ and Chamaida Plasencia-Rodriguez⁴, ¹Rheumatologyº, Hospital La Paz, Madrid, Spain, ²Immuno-Rheumatology Research group, La Paz University Hospital, Madrid, Spain, ³Rheumatology, La Paz University Hospital, Madrid, Spain, ⁴Hospital Universitario La Paz, Madrid, Spain, ⁵Rheumatology, University Hospital La Paz, IdiPaz, Madrid, Spain, ⁶Internal Medicine, Hospital Universitario La Paz, MADRID, Spain, ⁷Rheumatology, Rheumatology. La Paz University Hospital, Spain., Madrid, Spain
Background/Purpose:Anti-TNF has drastically changed the prognostic of the RA,carrying an important healthcare expense.This is why,optimisation seems a successful strategy that should not be linked to…
Abstract Number: 1472 • 2017 ACR/ARHP Annual Meeting
Body Mass Index Does Not Affect Response to Rituximab in Patients with Rheumatoid Arthritis: Results from Turkbio Registry
Suleyman Serdar Koca¹, Ahmet Karatas², Burak Oz³, Ediz Dalkilic⁴, Gerçek Can⁵, Yavuz Pehlivan⁶, Ayten Yazici⁷, Nevsun Inanc⁸, Ayse Cefle⁹, Zeypen Erturk¹⁰, Servet Akar¹¹, Soner Senel¹², Merih Birlik¹³, Nurullah Akkoc¹⁴ and Fatos Onen¹⁵, ¹Department of Rheumatology, Firat University School of Medicine, Elazig, Turkey, ²Department of Rheumatology, Firat University, School of Medicine, Rheumatology, Elazig, Turkey, ³Rheumatology, Firat University, School of Medicine, Rheumatology, Elazig, Turkey, ⁴Department of Internal Medicine, Division of Rheumatology, Uludag University, School of Medicine, Rheumatology, Bursa, Turkey, ⁵Rheumatology, Dokuz Eylul University Faculty of Medicine, İzmir, Turkey, ⁶Department of Rheumatology, Uludag University, Bursa, Turkey, ⁷Rheumatology, Kocaeli University, Kocaeli, Turkey, ⁸Departement of İnternal Medicine, Division of Rheumatology, Marmara University, Istanbul, Turkey, ⁹Rheumatology, Kocaeli University, School of Medicine, Rheumatology, Kocaeli, Turkey, ¹⁰Department of Rheumatology, Marmara Univeristy School of Medicine, Istanbul, Turkey, ¹¹Rheumatology, Izmir Katip Celebi University, School of Medicine, Rheumatology, Izmir, Turkey, ¹²Rheumatology, Kayseri Erciyes University, School of Medicine, Rheumatology, Kayseri, Turkey, ¹³Department of Rheumatology, Dokuz Eylul University School of Medicine, Izmir, Turkey, ¹⁴Rheumatology, Private Practice, Rheumatology, İzmir, Turkey, ¹⁵Rheumatology, Dokuz Eylul University Faculty of Medicine, Izmir, Turkey
Background/Purpose: Adipose tissue produces several inflammatory mediators. Thus, obesity affects the disease course and the responses to the anti-rheumatic agents in inflammatory diseases. Several previous…
Abstract Number: 1473 • 2017 ACR/ARHP Annual Meeting
Golimumab Improves Work Productivity and Activity Impairment in Patients with Rheumatoid Arthritis (RA), Ankylosing Spondylitis (AS) and Psoriatic Arthritis (PsA): Interim Results from a Non-Interventional Trial in Germany
Klaus Krüger¹, Sven Remstedt², Astrid Thiele³ and Ines Klaudius⁴, ¹Praxiszentrum St. Bonifatius München, München, Germany, ²Rheuma Praxis Berlin, Berlin, Germany, ³Krankenhaus St. Josef Wuppertal, Wuppertal, Germany, ⁴MSD Sharp & Dohme GmbH, Haar, Germany
Background/Purpose: In Germany no prospective data are available for Golimumab (GLM) in patients with RA, AS and PsAregarding outcomes evaluating work productivity and activity in…
Abstract Number: 1474 • 2017 ACR/ARHP Annual Meeting
A Higher DAS28P, the Subjective Proportion of the DAS28, Predicts a Favorable Response to Abatacept in Rheumatoid Arthritis
Jeong Seok Lee¹, HA Ahmad², Seung-Cheol Shim³, Sang-Cheol Bae⁴, Yeong Wook Song⁵ and Eun Young Lee⁶, ¹Division of Rheumatology, Department of Internal Medicine, Seoul National University Hospital, Seoul, Korea, Republic of (South), ²Bristol-Myers Squibb, Princeton, NJ, ³Division of Rheumatology, Department of Internal Medicine, Daejeon Rheumatoid & Degenerative Arthritis Center, Chungnam National University Hospital, Daejeon, Korea, Republic of (South), ⁴Department of Rhematology, Hanyang University Hospital for Rheumatic Diseases, Seoul, Korea, Republic of (South), ⁵WCU Department of Molecular Medicine and Biopharmaceutical Sciences, Medical Research Institute, Seoul National University College of Medicine, Seoul, Korea, Republic of (South), ⁶Seoul National University College of Medicine, Seoul, Korea, Republic of (South)
Background/Purpose: Response prediction of certain biologic agents for the treatment of rheumatoid arthritis (RA) is still an unmet need in real-world clinical practice. To reduce…
Abstract Number: 1475 • 2017 ACR/ARHP Annual Meeting
Collection of Anti-Rheumatic Medication Data from Both Patients and Rheumatologists Shows Strong Agreement in a Real World Clinical Cohort
Mohammad Movahedi, Angela Cesta, Xiuying Li and Claire Bombardier, Toronto General Hospital Research Institute, University Health Network, Toronto, ON, Canada
Background/Purpose: Collection of Anti-Rheumatic Medication (ARM) information from both patients and rheumatologists is considered a strength for Rheumatoid Arthritis (RA) registries and cohorts. However, it…
Abstract Number: 1476 • 2017 ACR/ARHP Annual Meeting
Effect of Treat-to-Target Tocilizumab- and Methotrexate-Based Strategies on Health-Related Quality of Life in Newly Diagnosed Rheumatoid Arthritis Patients: Results of the U-Act-Early Trial
Xavier M Teitsma¹, Johannes WG Jacobs¹, Paco MJ Welsing², Attila Pethö-Schramm³, Michelle EA Borm⁴, Jacob M. van Laar⁵, Floris PJ Lafeber⁵ and Johannes W.J. Bijlsma², ¹Department of Rheumatology & Clinical Immunology, University Medical Center Utrecht, Utrecht, Netherlands, ²Rheumatology and Clinical Immunology, University Medical Center Utrecht, Utrecht, Netherlands, ³F. Hoffmann-La Roche, Basel, Switzerland, ⁴Beneluxlaan 2a, Roche Nederland BV, Woerden, Netherlands, ⁵Rheumatology & Clinical Immunology, University Medical Center Utrecht, Utrecht, Netherlands
Background/Purpose: Patient-reported outcomes are, in addition to other efficacy and safety related outcomes, important reflections of effectiveness and adverse effects of a therapy. The Outcomes…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].